PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
56.59%
Positive revenue growth while CVE is negative. John Neff might see a notable competitive edge here.
169.31%
Positive gross profit growth while CVE is negative. John Neff would see a clear operational edge over the competitor.
346.02%
Positive EBIT growth while CVE is negative. John Neff might see a substantial edge in operational management.
346.02%
Positive operating income growth while CVE is negative. John Neff might view this as a competitive edge in operations.
93.57%
Positive net income growth while CVE is negative. John Neff might see a big relative performance advantage.
93.61%
Positive EPS growth while CVE is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
93.61%
Positive diluted EPS growth while CVE is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.03%
Share count expansion well above CVE's 0.01%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
No Data
No Data available this quarter, please select a different quarter.
-0.03%
Dividend reduction while CVE stands at 0.59%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-37.22%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-117.36%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
50.67%
10Y revenue/share CAGR at 50-75% of CVE's 95.76%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
-71.91%
Negative 5Y CAGR while CVE stands at 95.76%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
244.02%
3Y revenue/share CAGR above 1.5x CVE's 95.76%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
136.69%
Positive long-term OCF/share growth while CVE is negative. John Neff would see a structural advantage in sustained cash generation.
-66.16%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-47.37%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-159.62%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-107.51%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-112.83%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
24.14%
10Y equity/share CAGR above 1.5x CVE's 1.41%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-74.10%
Negative 5Y equity/share growth while CVE is at 1.41%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-67.48%
Negative 3Y equity/share growth while CVE is at 1.41%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
908.15%
10Y dividend/share CAGR above 1.5x CVE's 4.99%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
-0.47%
Negative 5Y dividend/share CAGR while CVE stands at 4.99%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-0.02%
Negative near-term dividend growth while CVE invests at 4.99%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-4.93%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-100.00%
Inventory is declining while CVE stands at 5.49%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-1.11%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-4.09%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
22.57%
Debt growth far above CVE's 1.15%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
1198.04%
We expand SG&A while CVE cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.